TY - JOUR
AU - Hadley, W. Keith
AB - Patients with AIDS and disseminated Mycobacterium avium complex (MAC) infection received rifampin (600 mg) plus ethambutol (25 mg/kg) plus ciprofloxacin (750 mg) or matching placebos daily for 8 weeks. Patients were monitored every 2 weeks clinically and by quantitating MAC colony-forming units (cfu) per milliliter of blood. Analysis of baseline characteristics revealed no significant differences between groups. After 8 weeks, MAC cfu had decreased by ⩾1 log/mL in 4 of 9 treated patients versus 0 of 10 placebo recipients while increasing by ⩾1 log/mL, in 1 and 7, respectively (P = .006). While the average combined clinical response score declined in both groups, it tended to decrease less in treated patients (P = .36). On the other hand, dose-limiting toxicity (primarily nausea and adverse drug interactions) occurred in 9 of 12 treatment versus 1 of 12 placebo patients (P = .005). Combined rifabutin-ethambutol-ciprofloxacin therapy for disseminated MAC infection had significant microbiologic efficacy with some evidence of clinical efficacy but was associated with drug intolerance.
TI - Randomized, Placebo-Controlled Trial of Rifampin, Ethambutol, and Ciprofloxacin for AIDS Patients with Disseminated Mycobacterium avium Complex Infection
JF - The Journal of Infectious Diseases
DO - 10.1093/infdis/168.1.112
DA - 1993-07-01
UR - https://www.deepdyve.com/lp/oxford-university-press/randomized-placebo-controlled-trial-of-rifampin-ethambutol-and-qTzpuuFL4P
SP - 112
EP - 119
VL - 168
IS - 1
DP - DeepDyve
ER -